

Supplementary Table SII Ovarian hyperstimulation syndrome (OHSS) in high risk women following kisspeptin-54 trigger.

OHSS screening Kisspeptin dosing group	Early OHSS			AD (CI) P value	Late OHSS			AD (CI) P value
	Single	Double	All		Single	Double	All	
<i>Number of patients diagnosed with OHSS*</i>								
Normal	30 (96.8%)	31 (100%)	61 (98.4%)		31 (100%)	30 (96.8%)	61 (98.4%)	
Mild	0	0	0		0	1 (3.2%)	1 (1.6%)	
Moderate	1 (3.2%)	0	1 (1.6%)		0	0	0	
Severe	0	0	0		0	0	0	
Critical	0	0	0		0	0	0	
<i>OHSS symptoms</i>								
Number of patients screened by OHSS symptoms (%)	31 (100%)	31 (100%)	62 (100%)		31 (100%)	31 (100%)	62 (100%)	
Number of patients with ≥1 symptom potentially consistent with OHSS (%)	9 (29.0%)	7 (22.6%)	16 (25.8%)		9 (29.0%)	9 (29.0%)	18 (29.0%)	
Number of patients requiring medical intervention for OHSS (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	
Number of patients requiring hospitalization for OHSS (%)	1 (3.2%)	0 (0.0%)	1 (1.6%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	
<i>Sonographic screening</i>								
Number of patients screened with pelvic ultrasound (%)	31 (100%)	30 (96.8%)	61 (98.4%)		30 (96.8%)	31 (100%)	61 (98.4%)	
Mean ovarian volume in ml (SD)	68.6 (52.1)	48.2 (28.9)	58.6 (43.2)	-20.4 (-39.3, -1.5) P = 0.034	28.9 (40.9)	16.1 (15.9)	22.4 (31.3)	-12.8 (-22.5, -3.3) P = 0.006
Mean ovarian diameter in mm (SD)	41.5 (10.1)	38.7 (7.9)	40.2 (9.1)		29.6 (9.9)	25.9 (6.0)	27.8 (8.3)	
Maximal ovarian diameter in mm (SD)	64.2 (15.1)	58.1 (11.0)	61.3 (13.6)	-6.1 (-12.9, 0.60) P = 0.079	44.7 (14.0)	42.4 (9.5)	43.5 (11.9)	-2.3 (-7.7, 3.1) P = 0.410
Number of patients with maximum ovarian diameter ≥5 cm (%)	24 (77.4%)	22 (73.3%)	46 (75.4%)		7 (23.3%)	7 (22.6%)	14 (23.0%)	
Number of patients with maximum ovarian diameter ≥8 cm (%)	5 (16.1%)	1 (3.3%)	6 (9.8%)		1 (3.3%)	0 (0.0%)	1 (1.6%)	
Number of patients with maximum ovarian diameter ≥12 cm (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	
Total free fluid in abdomen, POD/Adnexa in ml (SD)	5.8 (8.1)	3.4 (5.8)	4.6 (7.1)		3.0 (11.8)	0.8 (2.3)	1.9 (8.4)	
Number of patients with ≥ Grade 2 ascites (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	
Number of patients with pleural effusion (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	
<i>Blood parameters</i>								
Number of patients screened with Blood analysis (%)	31 (100%)	29 (93.5%)	60 (96.8%)		30 (96.8%)	31 (100%)	61 (98.4%)	
Number of patients with haematocrit >45% (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	
Number of patients with serum sodium ≥132 mmol/L (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	
Number of patients with serum potassium ≥5.0 mmol/L (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	
Number of patients with ALT ≥2 × ULN (%)	3 (9.7%)	1 (3.4%)	4 (6.7%)		1 (3.3%)	1 (3.2%)	2 (3.4%)	

Continued

Supplementary Table SII *Continued*

OHSS screening	Early OHSS				Late OHSS			
	Single	Double	All	AD (CI) P value	Single	Double	All	AD (CI) P value
Kisspeptin dosing group								
Number of patients with AST $\geq 2 \times$ ULN (%)	2 (6.5%)	1 (3.4%)	3 (5.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	
Number of patients with total protein ≥ 80 g/L (%)	1 (3.2%)	0 (0.0%)	1 (1.7%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	
Number of patient with creatinine ≥ 110 μ mol/L (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		1 (3.3%)	0 (0.0%)	1 (1.6%)	

Mean (SD) is presented for continuous variables and number of patients (%) for categorical variables.

*Diagnosis of OHSS was performed by two experienced IVF physicians (R.S. and S.L.) independent of the study team provided with blinded data according to the criteria of Golan *et al.* (1989) with updated categorization of severe and critical OHSS by Navot *et al.* (1992).

AD, absolute difference; CI, confidence interval; POD, pouch of douglas; ALT, alanine transaminase; AST, aspartate transaminase; ULN, upper limit of normal.

Reference

Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. *Fertil Steril* 1992;**58**:249–261.